Cargando…
MON-LB010 Cyclic Progesterone Therapy for Androgenic Polycystic Ovary Syndrome (PCOS) - A Systematic Review of the Literature
Women living with androgenic PCOS (WLWP) experience unpredictable oligomenorrhea(1) and are at increased risk for endometrial cancer(2). Oral micronized progesterone (OMP) given cyclically (14 days/cycle or 4 weeks, Cyclic OMP), in luteal phase doses(3) (300 mg at bedtime) as a “luteal phase replace...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209032/ http://dx.doi.org/10.1210/jendso/bvaa046.2339 |